ReviewThe American journal of gastroenterology2026
Biomarker Use in Barrett's Esophagus Surveillance.
Review in The American journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Barrett's esophagus (BE) is the established precursor to esophageal adenocarcinoma; however, the overwhelming majority of patients with BE never progress to cancer. Therefore, there is a clinical need to identify the patients with BE who are at high risk of progression from the patients with BE who will not progress. Histologic dysplasia has served as the marker of progression risk on which clinical decisions are made. However, dysplasia assessment in practice has been hindered by high interobserver variability. As such, many studies to develop validated biomarkers that either assist in dysplasia assessment or independently serve as predictors of progression risk have been performed. In this review, we will summarize some of these studies, primarily focused on p53, abnormal genomic content, and methylated DNA markers, which have shown promise for their ability to identify patients at increased risk of progressing to more advanced disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.